Financial Performance Highlights (Q1FY27)
Revenue: ₹450 crore, representing 17% year-over-year growth
EBITDA: ₹113 crore, representing 27% year-over-year growth
PAT (Profit After Tax): ₹57 crore, representing 26% year-over-year growth
Operational Performance Highlights
Volume Metrics:
- Patient volume grew 10% year-over-year
- Test volume increased 11% year-over-year
Revenue Segmentation:
- B2C revenue grew 18% year-over-year
- B2B revenue increased 15% year-over-year
- TruHealth revenue grew 22% year-over-year to ₹81 crore (18% of segment mix)
- Specialty revenue increased 17% year-over-year to ₹178 crore (40% of segment mix)
Productivity Metrics:
- Revenue per Patient (RPP) increased 6% year-over-year
- Revenue per Test (RPT) improved 5% year-over-year
Geographic Performance:
- Tier III cities: Revenue increased approximately 25% year-over-year
- Tier II cities: Revenue grew 14% year-over-year
- Tier I cities: Revenue grew 11% year-over-year
Premium Service Growth:
- Premium TruHealth packages grew over 50%
- Radiology-integrated wellness packages increased by more than 40%
Management Commentary
Ms. Ameera Shah, Promoter and Executive Chairperson: Highlighted industry consolidation around trusted providers, investments in scientific innovation and strategic acquisitions, and growth achieved without price increases. Emphasized focus on making high-quality diagnostics more accessible.
Mr. Surendran Chemmenkotil, Managing Director: Noted 210-basis point expansion in EBITDA margin, disciplined execution, resilience of business model, and focus on productivity and operational excellence.
Corporate Background
Established in 1981, Metropolis is India's second-largest diagnostic chain with:
- Presence across 28 states and 7 Union Territories
- Over 750+ towns coverage in India
- Network of more than 209 laboratories
- 5000+ service network
- Over 10,000 touchpoints
- Offers more than 4,500 tests and profiles
- Maintains CAP proficiency score of over 99.99% for past decade